Polymethyl methacrylate (PMMA) and related cosmetic ingredients methyl methacrylate crosspolymer and methyl methacrylate/glycol dimethacrylate crosspolymer are polymers that function as film formers and viscosity-increasing agents in cosmetics. The Food and Drug Administration (FDA) determination of safety of PMMA use in several medical devices, which included human and animal safety data, was used as the basis of safety of PMMA and related polymers in cosmetics by the Cosmetic Ingredient Review (CIR) Expert Panel. The PMMA used in cosmetics is substantially the same as in medical devices. The Panel concluded that these ingredients are safe as cosmetic ingredients in the practices of use and concentrations as described in this safety assessment.
Gottschalck TE,Bailey JEInternational Cosmetic Ingredient Dictionary and Handbook. 13th edWashington, DC: Personal Care Products Council (formerly the Cosmetic, Toiletry, and Fragrance Association; 2010:
2.
Description of Polymethyl Methacrylate Used in Cosmetics. Washington, DC: Council; 2009:1-1.
3.
Technical Data Sheet GanzPearl [pamphlet]. Somerset, NJ: Presperse, Incorporated; 2010:
4.
Test [pamphlet]. Santa Barbara, CA: Particle Sizing Systems,Inc; 2001:
Schoon D.A brief overview of polymer powders used in artificial nail enhancement systems. :
8.
Piacquadio D,Smith S,Anderson R.A comparison of commercially available polymethylmethacrylate-based soft tissue fillers.Dermatol Surg. 2008;34 (supp 1): S48-S52
9.
U.S.Food and Drug Administration. General and plastic surgery devices panel of the Medical Devices Advisory Committee. U.S. Food and Drug Administration. 2003. www.fda.gov/ohms/dockets/ac/03/transcripts/3934t1-am%20serssion.doc.1–196. Accessed February 8, 2010.
Cardre Inc. PMMA polymethyl methacrylate. www.cardre.com. Accessed April 15, 2010.
16.
Ganz Chemical Co.LTD. GanzPearl: Spherical fine polymer beads. 1–6. Date Accessed 2-9-2010.
17.
GanzPearl: Spherical fine polymer beads [pamphlet]. Minami Senba 1 Chome, Chuo-Ku, 542-0081 Osaka, Japan: Ganz Chemical Co, Ltd; 2001:13-27.
18.
Gonçalves OH,Nogueira AL,Schilischting R,Coan T,Sanches AAF,Machado RAF.Methyl methacrylate suspension polymerization: Strategies on particle size distribution.2nd Mercosur Congress on Chemical Engineering and 4th Mercosur Congress on Process Systems Engineering. 2005;:
19.
U.S.Food and Drug Administration. Quality system regulation. 2009. pp.CFR 820.1-820.250. Code of Federal Regulations:
20.
Standard analytical method (cosmetic GANZPEARL): Residual monomer (MMA, EGDM, and i-BMA) [pamphlet]. GANZ Chemical Co, Ltd;
Kaczmarczyk B,Morejko-Buz B,Stolarzewicz A.Investigation of infrared calibration methods for application to the study of methyl methacrylate polymerization.Fresenius J Anal Chem. 2001;370 (7): 899-903
23.
U.S.Food and Drug Administration. Class II Special Controls Guidance Document: Polymethylmathacrylate (PMMA) Bone Cement; Guidance for Industry and FDA. 7-17-2002. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm072795.htm#bio. Accessed June 19, 2009.
24.
Erckens RJ,March WF,Jongsma FH, et al.Noninvasive Raman spectroscopic identification of intraocular lens material in the living human eye.J Cataract Refract.Surg.. 2001;27 (7): 1065-1070
25.
Vallittu PK,Miettinen V,Alakuijala P.Residual monomer content and its release into water from denture base materials.Dent.Mater.. 1995;11 (6): 338-342
26.
Polymethyl methacrylate–Summary of clincial study. 2001;:1-1
27.
VCRP total number of products in each product category, May 2010. 2010:1-2
28.
Concentration of Use Polymethyl Methacrylate, Methyl Methacrylate Crosspolymer, Methyl Methacrylate/Glycol Dimethacrylate Crosspolymer and Sodium Polymethacrylate. Washington DC: ; 2009:1-3.
29.
FDA database. Cosmetic Production Fomulation and Frequency of Use Data. Washington, DC: FDA; 2009:
30.
Concentration of Use Polymethyl Methacrylate, Methyl Methacrylate Crosspolymer, Methyl Methacrylate/Glycol Dimethacrylate Crosspolymer and Sodium Polymethacrylate. Washington, DC: ; 2010:1-3.
31.
Health Canada. Use data for PMMA and related ingredients. 2010.
32.
James AC,Stahlhofen W,Rudolf G, et al.Deposition of inhaled particles.Ann ICRP. 1994;24 (1-3): 231-232
33.
Oberdorster G,Oberdorster E,Oberdorster J.Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles.Environ Health Perspect. 2005;113 (7): 823-839
34.
Lehman-McKeeman LDCasarett and Doull's Toxicology: The Basic Science of Poisons. 7th edKlassen CD, ed. New York, NY: McGraw-Hill Companies, Inc; 2008:131-159.
Johnson MA.The influence of particle size.Spray Technol Market. 2004;:24-27
37.
Environmental Working Group. Browse products containing polymethyl methacrylate. http://www.cosmeticsdatabase.com/browse.php?containing=705070&&showmore=products&atatime=500. Accessed February 15, 2010.
38.
Use of polymethyl methacrylate in artificial nail products. :
39.
Summary of Safety and Effectiveness Data: Tecnis Multifocal Intraocular Lens, Models ZM900 and ZMA00. :
40.
Summary of Safety and Effectiveness Data: Premarket Approval Application (PMA) Number P980040. :
41.
US Food and Drug Administration. 7-17-2002. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm072795.htm. Accessed June 19, 2009.
Summary of Safety and Effectiveness Data: ArteFill. :
45.
Premarket Notification: Temporary Crown and Bridge Material. :
46.
Brendolan A,Ronco C,Ghezzi PM,Scabardi M,La Greca G.Hydraulic and flow dynamic characteristics of PMMA dialyzers.Contrib Nephrol.. 1999;125:41-52
47.
Di Filippo S,Manzoni C,Locatelli F.Efficiency parameters and treatment adequacy of hemodialysis and hemodiafiltration using polymethylmethacrylate membranes.Contrib Nephrol.. 1999;125:86-95
48.
Sarnoff DS,Saini R,Gotkin RH.Comparison of filling agents for lip augmentation.Aesthet Surg J. 2008;28 (5): 556-563
49.
Dayan SH,Bassichis BA.Facial dermal fillers: selection of appropriate products and techniques.Aesthet Surg J.. 2008;28 (3): 335-347
Arevalo-Silva CA,Eavey RD,Cao Y,Vacanti M,Weng Y,Vacanti CA.Internal support of tissue-engineered cartilage.Arch Otolaryngol Head Neck Surg. 2000;126 (12): 1448-1452
53.
Tao S,Young C,Redenti S,Zhang Y,Klassen H,Desai T,Young MJ.Survival, migration and differentiation of retinal progenitor cells transplanted on micro-machined poly(methyl methacrylate) scaffolds to the subretinal space.Lab Chip. 2007;7 (6): 695-701
Broder KW,Cohen SR.ArteFill: a permanent skin filler.Expert Rev Med Devices.. 2006;3 (3): 281-289
56.
Sanna V,Gavini E,Giunchedi P.Bilayer tablets based on poly (epsilon-caprolactone) and polymethylmethacrilates as controlled-release systems for ruminants.Pharm Dev Technol.. 2004;9 (3): 321-328
57.
Nussbaum DA,Gailloud P,Murphy K.The chemistry of acrylic bone cements and implications for clinical use in image-guided therapy.J Vasc Interv Radiol.. 2004;15 ((2 Pt 1)): 121-126
Booth TM,Butson RJ,Clegg PD,Schramme MC,Smith RK.Treatment of sepsis in the small tarsal joints of 11 horses with gentamicin-impregnated polymethylmethacrylate beads.Vet Rec. 2001;148 (12): 376-380
60.
Feretis C,Benakis P,Dimopoulos C, et al.Endoscopic implantation of Plexiglas (PMMA) microspheres for the treatment of GERD.Gastrointest Endosc.. 2001;53 (4): 423-426
61.
Radhakrishnan VV,Saraswathy A,Rao VR,Rout D,Jayakrishnan A.Histopathological evaluation of polymethyl methacrylate as an embolic agent.Acta Neurochir (Wien).. 1992;117 ((1-2)): 30-33
62.
Batmanabane M,Malathi S,Ekandem GJ.Polymethyl methacrylate dissolved in chloroform as treatment for superficial digital injuries.Am J Surg. 1982;144 (5): 527
Biological Evaluation of Medical Devices–Part 5: Tests for in Vitro Cytotoxicity. Switzerland: International Organization for Standards; 2009:1-42.
65.
510(k) Summary; Cobalt™ HV Bone Cement. Washington, DC: U.S. Food and Drug Administration;
66.
Biological Evaluation of Medical Devices–Part 1: Evaluation and Testing. Switzerland: International organization for Statndards; 2003:
67.
Tecres Cemex® System Bone Cement; Special 510(k) Summary of Safety and Effectiveness. Washington, DC: U.S. Food and Drug Administration;
68.
510(k) Summary; SmarSet GHV Gentamicin Bone Cement. Washington, DC: U.S. Food and Drug Administration;
69.
510(k) Summary; Spine-Fix® Biomimetic Bone Cement. Washington, DC: U.S. Food and Drug Administration;
70.
510(K) Summary DePuy Orthopaedics, Inc. Washington, DC: U.S. Food and Drug Administration;
71.
Bigatti MP,Lamberti L,Cannas M,Rossi E.Lack of sister-chromatid exchange induction by polymethyl methacrylate bone cement in human lymphocytes cultured in vitro.Mutat Res. 1989;227 (1): 21-24
72.
PhillipsMK. Comment on Draft Report on PMMA 12-9-09. 2010.
73.
Guidance for Industry and FDA Staff: Dental Composite Resin Devices–Premarket Notification [510(k)] Submissions. Washington, DC: FDA; 2005:1-10.
74.
Oral Acute Toxicity Study of a Chemical Batch or Pharmaceutical Formulation in Male Mice: GANZ PEARL GM 0600. Not Clear. 1996:1-6.
75.
Determination of the Acute Ocular Irritation or Corrosion in Male Rabbits. Not Clear. 1996:1-6.
76.
Determination of the Acute Dermal Irritation or Corrosion in Male Rabbits. Not Clear. 1996:1-7.
77.
Summary of an HRIPT on a mascara containing 2.0% methyl methacrylate crosspolymer. 2008:
78.
Summary of an EpiOcular test on a mascara contianing 2.0% methyl methacrylate crosspolymer. 2008:
79.
Andersen FA.Amended final report on the safety assessment of ethyl methacrylate.Int J Toxicol. 2002;21 ((suppl 1)): 63-79
80.
Rustemeyer T,de Groot J,von Blomberg BME,Frosch PJ,Scheper RJ.Cross-reactivity patterns of contact-sensitizing methacrylates.Toxicol Appl Pharmacol. 1998;148 (1): 83-90
81.
Kanazawa Y,Yoshida T,Kojima K.Structure-activity relationships in allergic contact dermatitis induced by methacrylates.Contact Dermatitis. 1999;40 (1): 19-23
82.
Betts CJ,Dearman RJ,Heylings JR,Kimber I,Basketer DA.Skin sensitization potency of methyl methacrylate in the local lymph node assay: comparisons with guinea-pig data and human experience.Contact Dermatitis. 2006;55 (3): 140-147
